Epileptic disorders : international epilepsy journal with videotape · 2026
Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real-world clinical practice.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Benavente Álvaro Sánchez-Guijo, Martín Guillermina García, Ruiz Estuardo Daniel Castro, García Pablo Cabezudo, Moreno Yolanda López, María José Carlos Estévez, Fuentes Irene Lorite, Conti Sergio Navarro, Calle Raquel Calle, Cabrera Alejandro Fernández, González Isabel Ros, Blanco Dulce Campos, Muñoz María Isabel Chamorro, Castro Pedro Jesús Serrano
Аннотация
OBJECTIVE: Patients with drug-resistant epilepsy (DRE) typically take multiple anti-seizure medications (ASMs) and are at risk of treatment-related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug-resistant epilepsy.
METHODS: This was a multicenter (six Spanish epilepsy units), retrospective, observational study in patients with drug-resistant epilepsy who had received treatment with cenobamate as monotherapy (after conversion from polytherapy) or in dual therapy for at least three consecutive months, between April 2017 and November 2024.
RESULTS: In total, 125 patients (mean age 46 ± 15.9 years; median epilepsy duration 16 years, range: 1-65) were included. Median follow-up was 11 months (range 3-80). Patients had received a median of 5 (range 2-19) previous anti-seizure medications and were receiving a median of 2 (range 0-3) concomitant anti-seizure medications at cenobamate initiation; the most common concomitant anti-seizure medications were lacosamide (36%), brivaracetam (29.6%), and clobazam (26.4%). The median cenobamate dose at the last visit was 200 mg/day (range 100-400 mg/day). By the last visit, 31.5% of patients had achieved seizure freedom, and 75.8%, 58.1%, and 49.2% had achieved ≥50%, ≥75%, and ≥90% reductions in seizure frequency, respectively. During cenobamate treatment, 52% of patients discontinued one, 32% discontinued two, and 4% discontinued three concomitant anti-seizure medications. In total, 63/125 patients (50.4%) had adverse events during cenobamate treatment, all mild or moderate; 40.8% of patients had adverse events at the last visit. The most reported adverse events were somnolence (22.4%), dizziness (10.4%), fatigue (7.2%), and instability (4.8%).
SIGNIFICANCE: This study highlights the real-world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug-resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment-related adverse events without compromising seizure reduction.
METHODS: This was a multicenter (six Spanish epilepsy units), retrospective, observational study in patients with drug-resistant epilepsy who had received treatment with cenobamate as monotherapy (after conversion from polytherapy) or in dual therapy for at least three consecutive months, between April 2017 and November 2024.
RESULTS: In total, 125 patients (mean age 46 ± 15.9 years; median epilepsy duration 16 years, range: 1-65) were included. Median follow-up was 11 months (range 3-80). Patients had received a median of 5 (range 2-19) previous anti-seizure medications and were receiving a median of 2 (range 0-3) concomitant anti-seizure medications at cenobamate initiation; the most common concomitant anti-seizure medications were lacosamide (36%), brivaracetam (29.6%), and clobazam (26.4%). The median cenobamate dose at the last visit was 200 mg/day (range 100-400 mg/day). By the last visit, 31.5% of patients had achieved seizure freedom, and 75.8%, 58.1%, and 49.2% had achieved ≥50%, ≥75%, and ≥90% reductions in seizure frequency, respectively. During cenobamate treatment, 52% of patients discontinued one, 32% discontinued two, and 4% discontinued three concomitant anti-seizure medications. In total, 63/125 patients (50.4%) had adverse events during cenobamate treatment, all mild or moderate; 40.8% of patients had adverse events at the last visit. The most reported adverse events were somnolence (22.4%), dizziness (10.4%), fatigue (7.2%), and instability (4.8%).
SIGNIFICANCE: This study highlights the real-world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug-resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment-related adverse events without compromising seizure reduction.